Skip to main content
Delfa

← All assets

CT1812

9 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

9

Ongoing

1

Recruiting

0

Completed

7

Sites

121

Countries

5

Endpoints

87

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 87 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
3
Phase 1/2
1
Phase 2
4
Not applicable
1

Trials by status

Active, not recruiting
1
Completed
7
Unknown
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
29
Other (unclassified)
23
Fluid / digital biomarkers
14
Global cognition
6
Amyloid biomarkers
4
Function / daily living
3
Behavior / neuropsychiatric
2
Neurodegeneration biomarkers
2
Other clinical outcomes
2
Tau biomarkers
1
Neuroimaging
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 13 of 87 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADCS-Activities of Daily Living (ADCS-ADL)Function

3

Neurofilament light (NfL)Neurodeg.

2

Montreal Cognitive Assessment (MoCA)Cognition

2

Neuropsychiatric Inventory (NPI)Behavior

2

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

1

ADAS-CogCognition

1

Neurofilament light (NfL)Amyloid

1

Neurofilament light (NfL)Tau

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

9 of 9

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT05531656A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

CT1812

Alzheimer’s disease

MCI due to AD / mild AD dementiaPh 2Active, not recruiting50Apr 2027-
COG1201Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

CT1812

Lewy body dementia

Dementia with Lewy bodiesPh 2Completed34Nov 20241results
NCT03507790A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

CT1812

Alzheimer’s disease

mild-to-moderate ADPh 2Completed32May 20244results
NCT06961760Expanded Access Program for CT1812 (Zervimesine)

CT1812

Lewy body dementia

Dementia with Lewy bodiesNot applicableUnknown8-1
NCT02907567Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

CT1812

Alzheimer’s disease

mild-to-moderate ADPh 1/2Completed4Aug 20171
NCT03522129Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

CT1812

Alzheimer’s disease

Alzheimer's diseasePh 1Completed2Feb 20191
COG0108Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

CT1812

Alzheimer’s disease

Age 19-55Ph 1Completed1Jan 2022-results
COG0107Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers

CT1812

Alzheimer’s disease

Age 50-80Ph 1Completed1Jun 2022-
NCT04735536Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG

CT1812

Alzheimer’s disease

mild-to-moderate ADPh 2Completed1Apr 2023-results

Showing 1-9 of 9 trials